Evidence map›Paper›PMID 42208983›Full record

ArticleJournal for immunotherapy of cancer2026

Complete response to immune checkpoint blockade in sarcomatoid renal cell carcinoma with bone marrow metastasis: case report with tumor immune microenvironment profiling.

Yuji Miura, Ryosuke Jikuya, Asaki Saijo, Hiromu Yano, Keiichi Kinowaki, Kohji Takemura, Keita Uchino, Hisashi Hasumi, Yoshihiro Komohara

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuji MiuraDepartment of Medical Oncology, Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto, Tokyo, Japan yuji.miura@jfcr.or.jp.ORCID http://orcid.org/0000-0002-7091-628X
Ryosuke JikuyaDepartment of Urology, Yokohama City University, Yokohama, Japan.
Asaki SaijoDepartment of Medical Oncology, Toranomon Hospital, Minato, Japan.
Hiromu YanoDepartment of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan.
Keiichi KinowakiDepartment of Pathology, Toranomon Hospital, Minato, Tokyo, Japan.
Kohji TakemuraDepartment of Medical Oncology, Toranomon Hospital, Minato, Japan.
Keita UchinoDepartment of Medical Oncology, Toranomon Hospital, Minato, Japan.
Hisashi HasumiDepartment of Urology, Yokohama City University, Yokohama, Japan.
Yoshihiro KomoharaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow represents a unique microenvironment enriched with both immunosuppressive cells and immune-activating functions. However, its role in metastasis and response to immunotherapy remains poorly understood. We report a case of sarcomatoid clear cell renal cell carcinoma with systemic bone marrow metastasis that achieved a complete response to ipilimumab plus nivolumab. Using matched pretreatment and post-treatment bone marrow samples, we performed integrative immune profiling. Pretreatment analyses showed abundant CD14

Indexed as

Bone Marrow NeoplasmsCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsTumor MicroenvironmentFemaleHumansIpilimumabMalePathologic Complete ResponseImmune Checkpoint InhibitorsIpilimumabIpilimumabMyeloid-derived suppressor cell - MDSCNivolumabRenal Cell Carcinoma

Identifiers

PMID42208983
PMCPMC13223640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.